FDA.reportPublic FDA data

REZUROCK 200 MG Oral Tablet

RxCUI
2564037
RxNorm name
REZUROCK 200 MG Oral Tablet
Display name
REZUROCK 200 MG Oral Tablet
Full name
REZUROCK 200 MG Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RezurockBELUMOSUDILKadmon Pharmaceuticals, LLC102e4ef4-7f84-4e34-8df1-479c24d1575d2026-04-07Warnings, Adverse reactionsExact identifier
rxcui: 2564037

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
102e4ef4-7f84-4e34-8df1-479c24d1575dREZUROCK 200 MG Oral Tablet [PSN] · belumosudil 200 MG Oral Tablet [Rezurock] [SBD] · Rezurock 200 MG (as belumosudil mesylate 242.5 MG) Oral Tablet [SY] · Rezurock 200 MG Oral Tablet [SY]411These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK. REZUROCK ® (belumosudil) tablets, for oral use Initial U.S. Approval: 202120260407